Differentiating ischemic stroke subtypes: Risk factors and secondary prevention

Journal of the Neurological Sciences

Volumn 279, Issue 1-2, 2009, Pages 1-8

  Kirshner, Howard S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Ischemic stroke subtype; Large vessel disease; Risk factors; Secondary prevention; Small vessel disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALCOHOL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; IRBESARTAN; WARFARIN;

ABDOMINAL OBESITY; ACUTE CORONARY SYNDROME; ALCOHOL CONSUMPTION; BLEEDING; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INFECTION; INTERVENTION STUDY; LIFESTYLE MODIFICATION; MONOTHERAPY; PERIPHERAL CIRCULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SURGICAL TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ALCOHOL DRINKING; BRAIN ISCHEMIA; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DYSLIPIDEMIAS; ETHNIC GROUPS; HUMANS; HYPERTENSION; INFECTION; OBESITY; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; SMOKING; STROKE;

EID: 61349119915     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.12.012     Document Type: Review

References (86)

1. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., et al. Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Kelly-Hayes M., Beiser A., Kase C.S., Scaramucci A., D'Agostino R.B., and Wolf P.A. The influence of gender and age on disability following ischemic stroke: the Framingham study. J Stroke Cerebrovasc Dis 12 (2003) 119-126
3. Hankey G.J., Spiesser J., Hakimi Z., Bego G., Carita P., and Gabriel S. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology 68 (2007) 1583-1587
4. Hardie K., Hankey G.J., Jamrozik K., Broadhurst R.J., and Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 35 (2004) 731-735
5. Steg P.G., Bhatt D.L., Wilson P.W., D'Agostino Sr. R., Ohman E.M., Rother J., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
6. Adams R.J., Albers G., Alberts M.J., Benavente O., Furie K., Goldstein L.B., et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39 (2008) 1647-1652
7. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
8. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 630S-669S
9. Ohira T., Shahar E., Chambless L.E., Rosamond W.D., Mosley Jr. T.H., and Folsom A.R. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke 37 (2006) 2493-2498
10. Petty G.W., Brown Jr. R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., Fallon, and Wiebers D.O. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30 (1999) 2513-2516
11. Schulz U.G., and Rothwell P.M. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34 (2003) 2050-2059
12. Jackson C., and Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke 36 (2005) 891-901
13. Grau A.J., Weimar C., Buggle F., Heinrich A., Goertler M., Neumaier S., et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32 (2001) 2559-2566
14. Kitamura A., Nakagawa Y., Sato M., Iso H., Sato M., Imano H., et al. Proportions of stroke subtypes among men and women > or = 40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 37 (2006) 1374-1378
15. Kolominsky-Rabas P.L., Weber M., Gefeller O., Neundoerfer B., and Heuschmann P.U. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 32 (2001) 2735-2740
16. Shin D.H., Lee P.H., and Bang O.Y. Mechanisms of recurrence in subtypes of ischemic stroke: a hospital-based follow-up study. Arch Neurol 62 (2005) 1232-1237
17. Uchino K., Risser J.M., Smith M.A., Moye L.A., and Morgenstern L.B. Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites: the BASIC Project. Neurology 63 (2004) 574-576
18. Petty G.W., Brown Jr. R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., and Wiebers D.O. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 31 (2000) 1062-1068
19. Lovett J.K., Coull A.J., and Rothwell P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62 (2004) 569-573
20. Moroney J.T., Bagiella E., Paik M.C., Sacco R.L., and Desmond D.W. Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke 29 (1998) 2118-2124
21. Lai S.L., Weng H.H., Lee M., Hsiao M.C., Lin L.J., and Huang W.Y. Risk factors and subtype analysis of acute ischemic stroke. Eur Neurol 60 (2008) 230-236
22. Tirschwell D.L., Smith N.L., Heckbert S.R., Lemaitre R.N., Longstreth Jr. W.T., and Psaty B.M. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63 (2004) 1868-1875
23. Paganini-Hill A., Lozano E., Fischberg G., Perez Barreto M., Rajamani K., Ameriso S.F., et al. Infection and risk of ischemic stroke: differences among stroke subtypes. Stroke 34 (2003) 452-457
24. Di Carlo A., Lamassa M., Baldereschi M., Pracucci G., Consoli D., Wolfe C.D., et al. Risk factors and outcome of subtypes of ischemic stroke. Data from a multicenter multinational hospital-based registry. The European Community Stroke Project. J Neurol Sci 244 (2006) 143-150
25. Murat Sumer M., and Erturk O. Ischemic stroke subtypes: risk factors, functional outcome and recurrence. Neurol Sci 22 (2002) 449-454
26. Kool M.J., Hoeks A.P., Struijker Boudier H.A., Reneman R.S., and Van Bortel L.M. Short- and long-term effects of smoking on arterial wall properties in habitual smokers. J Am Coll Cardiol 22 (1993) 1881-1886
27. Krobot K., Hense H.W., Cremer P., Eberle E., and Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. Arterioscler Thromb 12 (1992) 780-788
28. Reynolds K., Lewis B., Nolen J.D., Kinney G.L., Sathya B., and He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 289 (2003) 579-588
29. Leppala J.M., Virtamo J., Fogelholm R., Albanes D., and Heinonen O.P. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 30 (1999) 2535-2540
30. Suk S.H., Sacco R.L., Boden-Albala B., Cheun J.F., Pittman J.G., Elkind M.S., et al. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 34 (2003) 1586-1592
31. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., and Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162 (2002) 1867-1872
32. Dauchet L., Amouyel P., and Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology 65 (2005) 1193-1197
33. Van de Wiel A., and Caillard C.A. Statins and the stroke-cholesterol paradox. Neth J Med 60 (2002) 4-9
34. Laloux P., Galanti L., and Jamart J. Lipids in ischemic stroke subtypes. Acta Neurol Belg 104 (2004) 13-19
35. Song Y.M., Kwon S.U., Sung J., Ebrahim S., Smith G.D., Sunwoo S., et al. Different risk factor profiles between subtypes of ischemic stroke. A case-control study in Korean men. Eur J Epidemiol 20 (2005) 605-612
36. Vibo R., Korv J., Roose M., Kampus P., Muda P., Zilmer K., et al. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic Res 41 (2007) 282-287
37. Petersen N.H., Schmied A.B., Zeller J.A., Plendl H., Deuschl G., and Zunker P. Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. Cerebrovasc Dis 23 (2007) 188-193
38. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
39. Plehn J.F., Davis B.R., Sacks F.M., Rouleau J.L., Pfeffer M.A., Bernstein V., et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99 (1999) 216-223
40. Waters D.D., Schwartz G.G., Olsson A.G., Zeiher A.G., Oliver M.F., Ganz P., et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695
41. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
42. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 33 (2002) 862-875
43. Briel M., Studer M., Glass T.R., and Bucher H.C. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 117 (2004) 596-606
44. Corvol J.C., Bouzamondo A., Sirol M., Hulot J.S., Sanchez P., and Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 163 (2003) 669-676
45. Nomura E., Kohriyama T., Matsumoto M., and Kobayashi S. Clinical characteristics of first-ever atherothrombotic infarction or lacunar infarction with hyperlipidemia (J-STARS-C): an analysis of data from the stroke data bank of Japan. Intern Med 44 (2005) 1252-1257
46. Rashid P., Leonardi-Bee J., and Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 34 (2003) 2741-2748
47. SPS3 Collaborators. Secondary Prevention of Small Subcortical Strokes (May 9, 2007). http://www.sps3.org Available from: www.sps3.org. Cited December 19, 2007
48. Hankey G., Jamrozik K., Broadhurst R.J., Forbes S., Burvill P.W., Anderson C.S., et al. Long-term risk of first recurrent stroke in the Perth community stroke study. Stroke 29 (1998) 2491-2500
49. Bouhanick B., Cambou J.P., Ferrieres J., Amelineau E., and Guize L. Characteristics and six-month outcomes in a cohort of 8288 diabetic and non-diabetic patients with previous history of acute coronary syndrome or stroke: the French PREVENIR 3 survey. Diabetes Metab 32 (2006) 460-466
50. Goede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
51. National Heart, Lung and Blood Institute. For Safety, NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease. NIH News. February 6, 2008. Available from: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. Cited February 15, 2008.
52. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
53. Macko R.F., Ameriso S.F., Barndt R., Clough W., Weiner J.M., and Fisher M. Precipitants of brain infarction. Roles of preceding infection/inflammation and recent psychological stress. Stroke 27 (1996) 1999-2004
54. Grau A.J., Buggle F., Lichy C., Brandt T., Becher H., and Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci 186 (2001) 1-5
55. Heuschmann P.U., Neureiter D., Gesslein M., Craiovan B., Maass M., Faller G., et al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke 32 (2001) 2253-2258
56. Lindsberg P.J., and Grau A.J. Inflammation and infections as risk factors for ischemic stroke. Stroke 34 (2003) 2518-2532
57. Eikelboom J.W., Hankey G.J., Anand S.S., Lofthouse E., Staples N., and Baker R.I. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 31 (2000) 1069-1075
58. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
59. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299 (1978) 53-59
60. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
61. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
62. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251
63. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., and Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
64. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
65. De Schryver E.L., Algra A., and van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2 (2006) [CD001820]
66. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
67. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
68. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
69. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
70. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
71. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
72. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
73. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
74. Kennedy J., Hill M.D., Ryckborst K.J., Eliasziw M., Demchuk A.M., and Buchan A.M. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6 (2007) 961-969
75. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
76. Hart R.G., Bhatt D.L., Hacke W., Fox K.A., Hankey G.J., Berger P.B., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis 25 (2008) 344-347
77. Mohr J.P., Thompson J.L., Lazar R.M., Levin B., Sacco R.L., Furie K.L., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
78. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291 (2004) 576-584
79. Homma S., Sacco R.L., Di Tullio M.R., Sciacca R.R., and Mohr J.P. Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol 42 (2003) 1066-1072
80. Ariesen M.J., Algra A., and Kappelle L.J. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 37 (2006) 134-138
81. Elkind M.S. Implications of stroke prevention trials: treatment of global risk. Neurology 65 (2005) 17-21
82. Ovbiagele B., Saver J.L., Fredieu A., Suzuki S., McNair N., Dandekar A., et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 63 (2004) 1217-1222
83. Ovbiagele B., Saver J.L., Fredieu A., Suzuki S., Selco S., Rajajee V., et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 35 (2004) 2879-2883
84. Smaha L.A. The American Heart Association Get With The Guidelines program. Am Heart J 148 (2004) S46-S48
85. American Stroke Association. New study targets long-term stroke prevention adherence (May 31, 2006). http://www.medicalnewstoday.com/medicalnews.php?newsid=44252 Available from: http://www.medicalnewstoday.com/medicalnews.php?newsid=44252. Cited May 22, 2007
86. Yip P.K., Jeng J.S., Lee T.K., Chang Y.C., Huang Z.S., Ng S.K., et al. Subtypes of ischemic stroke. A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 28 (1997) 2507-2512